| I |
Original contributions |
| a) |
Senior authorship |
| 1. |
Burkhard O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T, Haller H,
Fliser D, Kielstein JT. Pharmacokinetics of Ertapenem
in critically ill patients with acute renal failure undergoing extended
daily dialysis. Nephrol Dial Transplant, 2008; in press.
|
| 2. |
Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D,
Kielstein JT. The Hannover-Dialysis-Outcome
(HAN-D-OUT)-study: Comparison of standard versus intensified extended
dialysis in treatment of patients with acute kidney injury in the
intensive-care unit. Nephrol Dial Transplant, 2008; in press.
|
| 3. |
Czock D, Hüsig-Linde C, Langhoff A, Schöpke T, Hafer C, de Groot
K, Swoboda S, Kuse E, Haller H, Fliser D, Keller F, Kielstein
JT. Clin J Am Soc Nephrol 2006; 1: 1263-1268.
PDF
|
| b) |
First / equally contributed first authorship |
| 1. |
Kielstein JT, Salpeter SR, Buckley NS, Cooke JP,
Fliser D. Two cardiovascular risk factors in one? Homocysteine and its
relation to glomerular filtration rate. A meta-analysis of 41 studies with
27,000 participants. Blood Purification DOI 10.1159/000142725.
PDF
|
| 2. |
Peter C, Kielstein JT, Clarke-Katzenberg R, Adams MC,
Pitsiouni M, Kambham N, Karimi MA, Kengatharan KM, Cooke JP. A novel
bioluminescent tumor model of human renal cancer cell lines: an in vitro
and in vivo characterization. J Urology. 2007; 177(6):2342-2346.
|
| 3. |
Kalousova M, Kielstein JT, Hodkova M, Zima T,
Dusilova-Sulkova S, Martens-Lobenhoffer J, Bode-Böger SM. No Benefit of
Hemodiafiltration over Hemodialysis in Lowering Elevated Levels of Asymmetric
Dimethylarginine in ESRD Patients. Blood Purif. 2006; 24(5):439-444.
PDF
|
| 4. |
Kielstein JT, Donnerstag F, Gasper S, Menne J,
Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D,
Bode-Böger SM. ADMA increases arterial stiffness and decreases
cerebral blood flow in human. Stroke 2006; 37(8):2024-9.
PDF
|
| 5. |
Kielstein JT, Salpeter S, Bode-Böger SM, Cooke
JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of
renal function—a meta-analysis. Nephrol Dial Transplant 2006;
21(9):2446-51.
|
| 6. |
Kielstein JT, Czock D, Schöpke T, Hafer C,
Bode-Böger SM, Kuse E, Keller F, Fliser D. Pharmacokinetics and total
elimination of meropenem and vancomycin in intensive care unit patients
undergoing extended daily dialysis. Crit Care Med 2006;34: 51-56.
PDF
|
| 7. |
Kielstein JT, Bode-Böger SM, Hesse G,
Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM. Asymmetrical
dimethylarginine in idiopathic pulmonary arterial hypertension.
Arterioscler Thromb Vasc Biol 2005; 25: 1414-1418.
|
| 8. |
Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr
MJ, Haller H, Fliser D. Efficacy and cardiovascular tolerability of extended
dialysis in critically ill patients: a randomized controlled study. Am
J Kidney Dis 2004; 43: 342-349.
|
| 9. |
Kielstein JT, Boger RH, Bode-Böger SM,
Martens-Lobenhoffer J, Lonnemann G, Frölich JC, Haller H, Fliser D.
Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro
evidence of significant protein binding. Clin Nephrol 2004; 62:
295-300.
PDF
|
| 10. |
Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ,
Schmidt-Gayk H, Haller H, Fliser D. Subpressor dose Asymmetric
dimethylarginine modulates renal blood flow through nitric oxide synthase
inhibition. Kidney Blood Press Res 2004; 27: 143-147.
PDF
|
| 11. |
Kielstein JT, Impraim B, Simmel S, Bode-Böger
SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D.
Cardiovascular effects of systemic nitric oxide synthase inhibition with
asymmetrical dimethylarginine in humans. Circulation 2004; 109:
172-177.
PDF
|
| 12. |
Kielstein JT, Linnenweber S, Schoepke T, Fliser D.
One for all--a multi-use dialysis system for effective treatment of severe
thallium intoxication. Kidney Blood Press Res 2004; 27: 197-199.
|
| 13. |
Kielstein JT, Becker B, Graf S, Brabant G, Haller H,
Fliser D. Increased resistin blood levels are not associated with insulin
resistance in patients with renal disease. Am J Kidney Dis 2003;
42: 62-66.
|
| 14. |
Kielstein JT, Bode-Böger SM, Klein G, Graf S,
Haller H, Fliser D. Endogenous nitric oxide synthase inhibitors and renal
perfusion in patients with heart failure. Eur J Clin Invest 2003;
33: 370-375.
PDF
|
| 15. |
Kielstein JT, Bode-Böger SM, Frölich JC,
Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine (ADMA), blood
pressure and renal perfusion in elderly subjects. Circulation 2003;
107: 1891-1895.
PDF
|
| 16. |
Kielstein JT, Woywodt A, Schumann G, Haller H,
Fliser D. Efficiency of high-flux hemodialysis in the treatment of
valproic acid intoxication. J Toxicol Clin Toxicol 2003; 41:
873-876.
|
| 17. |
Kielstein JT, Böger RH, Bode-Böger SM,
Frölich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric
dimethylarginine in patients with incipient primary chronic renal disease.
J Am Soc Nephrol 2002; 13: 170-176.
PDF
|
| 18. |
Kielstein JT, Böger RH, Bode-Böger SM,
Schäffer J, Barbey M, Koch KM, Frölich JC. Asymmetric
dimethylarginine plasma concentrations differ in patients with end-stage
renal disease: relationship to treatment method and atherosclerotic
disease. J Am Soc Nephrol 1999; 10: 594-600.
PDF
|
| c) |
Co-authorship |
| 1. |
Menne J, Park JK, Agrawal R, Lindschau C, Kielstein JT,
Kirsch T, Marx A, Müller D, Bahlmann FH, Meier M,
Bode-Böger SM, Haller H, Fliser D. Cellular and molecular mechanisms
of tissue protection by lipophilic calcium channel blockers. FASEB J
2006 ; 20: 994-996.
PDF
|
| 2. |
Bode-Böger SM, Scalera F, Kielstein JT,
Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H. Symmetrical
dimethylarginine: a new combined parameter for renal function and extent
of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-1134.
PDF
|
| 3. |
Fliser D, Kronenberg F, Kielstein JT, Morath C,
Bode-Böger SM, Haller H, Ritz E. Asymmetric dimethylarginine and
progression of chronic kidney disease. The mild to moderate kidney disease
study. J Am Soc Nephrol 2005; 16: 2456-2461.
|
| 4. |
Scalera F, Kielstein JT, Martens-Lobenhoffer J,
Postel S, Tager M, Bode-Böger SM. Erythropoietin increases asymmetric
dimethylarginine (ADMA) in endothelial cells – role of Dimethylarginine
Dimethylaminohydrolase (DDAH). J Am Soc Nephrol 2005; 16: 892-898.
|
| 5. |
Becker B, Kronenberg F, Kielstein JT, Haller H,
Morath C, Ritz E, Fliser D. Renal insulin resistance syndrome, adiponectin
and cardiovascular events in patients with kidney disease: the mild to
moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
|
| 6. |
Woywodt A, Herrmann A, Kielstein JT, Haller H,
Haubitz M, Purnhagen H. A novel multimedia tool to improve bedside teaching
of cardiac auscultation. Postgrad Med J 2004; 80(944):355-357.
|
| 7. |
Kaiser T, Hermann A, Kielstein JT, Wittke S, Bartel
S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H,
Weissinger EM, Fliser D, Mischak H. Capillary electrophoresis coupled to
mass spectrometry to establish polypeptide patterns in dialysis fluids.
J Chromatogr A 2003; 1013: 157-1571.
|
| 8. |
Terkamp C, Kirchner G, Wedemeyer J, Dettmer A, Kielstein
JT, Reindell H, Bleck J, Manns M, Gebel M. Simulation of abdomen
sonography. Evaluation of a new ultrasound simulator. Ultraschall Med
2003; 24: 239-244.
|
| 9. |
Bode-Böger SM, Böger RH, Kielstein JT,
Löffler M, Schäffer J, Frölich JC. Role of endogenous nitric
oxide in circadian blood pressure regulation in healthy humans and in
patients with hypertension or atherosclerosis. J Investig Med 2000;
48: 125-132.
|
| 10. |
Widjaja A, Kielstein JT, Horn R, von zur Mühlen
A, Kliem V, Brabant G. Free serum leptin but not bound leptin
concentrations are elevated in patients with end-stage renal disease.
Nephrol Dial Transplant 2000; 15: 846-850.
|
| II |
Editorials/ Reviews / Case reports / Letter |
| a) |
Editorials |
| 1. |
Kielstein JT, Sydow K. Glomerular filtration and
coronary flow: is ADMA the faucet regulating both? Am J Hypertens
2008; 21:601-602.
|
| 2. |
Kielstein JT, Tsao PS. From Zanius to ADMA: ADMA-a
new "adipocytokine" and its potential role in metabolic syndrome. J
Nephrol 2007; 20:554-559.
|
| 3. |
Kielstein JT, Fliser D. Lowering Asymmetric
Dimethylarginine - A New Mechanism Mediating the Renoprotective Effects of
Renin-Angiotensin System Inhibitors in Proteinuric Patients? Blood Purif
2007; 25(4):324-326.
|
| 4. |
Kielstein JT, Zoccali C. A new perspective for the
treatment of renal diseases? J Am Soc Nephrol 2007:18:1365-1367.
|
| 5. |
Kielstein JT, Cooke JP, Should we measure ADMA in
patients with coronary artery disease? Clin Chem 2007; 53(2):
161 - 163.
|
| b) |
Reviews |
| 1. |
Kielstein JT & Fliser D. Acute renal failure:
Extracorporeal therapy. Internist (Berl). 2007;48:786-794.
|
| 2. |
Kielstein JT & Fliser D. Ther past presence and
future of ADMA in Nephrology. Nephrol Ther. 2007;3(2):47-54.
|
| 3. |
Fliser D, Kielstein JT, Menne J. Insulin resistance
in renal disease. Contrib Nephrol 2006; 151: 203–211.
|
| 4. |
Zoccali C, Kielstein JT. Asymmetric
dimethylarginine: a new player in the pathogenesis of renal disease? Curr
Opin Nephrol Hypertens 2006; 15: 314-320.
PDF
|
| 5. |
Fliser D, Kielstein JT. Technology Insight:
treatment of renal failure in the intensive care unit with extended
dialysis. Nature Clinical Practice Nephrology 2006; 2: 32-39.
PDF
|
| 6. |
Kielstein JT, Tsikas D, Fliser D. Effects of
Asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin
Pharmacol 2005; 14: 1-6.
|
| 7. |
Kielstein JT, Zoccali C. Asymmetyric
Dimethylarginine: A cardiovascular risk factor and a uremic toxin coming
of age? Am J Kidney Dis 2005; 46: 186-202.
|
| 8. |
Fliser D, Kielstein JT. A single-pass batch dialysis
system: an ideal dialysis method for the patient in intensive care with
acute renal failure. Curr Opin Crit Care 2004, 10: 483-488.
|
| 9. |
Fliser D, Kielstein JT, Haller H, Bode-Böger
SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal
disease? Kidney Int Suppl 2003; (Suppl 84): S37-S40.
PDF
|
| 10. |
Kielstein JT, Bode-Böger SM, Haller H, Fliser
D. Functional changes in the ageing kidney: is there a role for asymmetric
dimethylarginine? Nephrol Dial Transplant 2003; 18: 1245-1248.
PDF
|
| 11. |
Kielstein JT, Frölich JC, Haller H, Fliser D.
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating
agent in patients with renal disease? Nephrol Dial Transplant 2001;
16: 1742-1745.
PDF
|
| 12. |
Kielstein JT, Bode-Böger SM, Frölich JC,
Haller H, Böger RH. Relationship of asymmetric dimethylarginine to
dialysis treatment and atherosclerotic disease. Kidney Int Suppl
2001; (Suppl 78): S9-S13.
|
| c) |
Case reports |
| 1. |
Clajus B, Becker JU, Stichtenoth DO, Wortmann J, Schwarz A,
Kielstein JT. Acute kidney injury due to deferoxamine
in a renal transplant patient. Nephrol Dial Transplant,
2008;23(3):1061-4.
|
| 2. |
Burkhardt O, Joukhadar C, Traunmüller F, Hadem J, Welte T,
Kielstein JT. Elimination of Daptomycin in a patient
with acute renal failure undergoing extended daily dialysis. Journal of
Antimicrobial Chemotherapy, 2008;61(1):224-5.
|
| 3. |
Kielstein JT, Stadler M, Czock D, Keller F,
Hertenstein B, Radermacher J. Dialysate concentration and pharmacokinetics
of 2F-Ara-A in a patient with acute renal failure. Eur J Haematology.
2005; 74: 533-534.
PDF
|
| 4. |
Kielstein JT, Linnenweber S, Schoepke T, Fliser D.
One for all--a multi-use dialysis system for effective treatment of severe
thallium intoxication. Kidney Blood Press Res 2004; 27: 197-199.
|
| 5. |
Kielstein JT, Schwarz A, Arnavaz A, Sehlberg O,
Emrich HM, Fliser D. High-flux hemodialysis-an effective alternative to
hemoperfusion in the treatment of carbamazepine intoxication. Clin
Nephrol 2002; 57: 484-486.
|
| 6. |
Woywodt A, Kielstein JT, Haller H. An uncommon
cause of metabolic acidosis in a haemodialysis patient. Nephrol Dial
Transplant 2002; 17: 929-930.
|
| 7. |
Kielstein JT, Abou-Rebyeh F, Hafer C, Haller H,
Fliser D. Right-sided chest pain at the onset of haemodialysis. Nephrol
Dial Transplant 2001; 16: 1493-1495.
|
| 8. |
Kielstein JT, Helmchen U, Netzer KO, Weber M,
Haller H, Floege J. Conversion of Goodpasture's syndrome into membranous
glomerulonephritis. Nephrol Dial Transplant 2001; 16: 2082-2085.
|
| 9. |
Woywodt A, Kielstein JT, Winkler M. Clinical
picture: Subphrenic abscess and rupture of the spleen. Lancet 2001;
358: 875.
|
| 10. |
Kielstein JT, Termühlen L, Sohn J, Kliem V.
Minimal change nephrotic syndrome in a 65-year-old patient following
influenza vaccination. Clin Nephrol 2000; 54: 246-248.
|
| d) |
Letter |
| 1. |
Kielstein JT, Sydow K, Thum T. Tilarginine in
patients with acute myocardial infarction and cardiogenic shock. JAMA
2007; 298(9):971.
|
| 2. |
Kielstein JT, Woywodt A, Salpeter SR. Letter by
Kielstein et al regarding article, "High-dose allopurinol improves
endothelial function by profoundly reducing vascular oxidative stress and
not by lowering uric acid". Circulation 2007; 8:115(18):e450-1.
|
| 3. |
Kielstein JT, Peter C, Adams MC. Cigarettes and
ADMA: The Smoke Hasn't Cleared Yet. Hypertension 2006; 48:E20.
|
| 4. |
Kielstein JT, Cooke JP, Zoccali C. Letter regarding
article "Renal Function as a Predictor of Outcome in a Broad
Spectrum of Patients With Heart Failure." Circulation 2006;
114: e242.
|
| 5. |
Kielstein JT, Cooke JP. Arginine Metabolism,
Pulmonary Hypertension, and Sickle Cell Disease. JAMA 2005; 294:
2432-2432.
|
| 6. |
Tsikas D, Frölich JC, Kielstein JT. Nitric
oxide synthesis in chronic renal failure. Are plasma S-nitrosothiol levels
elevated? Clin Chim Acta 2004; 339: 195-197.
PDF
|